These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 22691216

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Simultaneous inhibition of c-Abl and Src kinases abrogates the exaggerated expression of profibrotic genes in cultured systemic sclerosis dermal fibroblasts.
    Piera-Velazquez S, Jimenez SA.
    Clin Exp Rheumatol; 2018; 36 Suppl 113(4):36-44. PubMed ID: 30277861
    [Abstract] [Full Text] [Related]

  • 7. Imatinib mesylate and AMN107 inhibit PDGF-signaling in orbital fibroblasts: a potential treatment for Graves' ophthalmopathy.
    van Steensel L, Paridaens D, Schrijver B, Dingjan GM, van Daele PL, van Hagen PM, van den Bosch WA, Drexhage HA, Hooijkaas H, Dik WA.
    Invest Ophthalmol Vis Sci; 2009 Jul; 50(7):3091-8. PubMed ID: 19234339
    [Abstract] [Full Text] [Related]

  • 8. Imatinib mesylate blocks a non-Smad TGF-beta pathway and reduces renal fibrogenesis in vivo.
    Wang S, Wilkes MC, Leof EB, Hirschberg R.
    FASEB J; 2005 Jan; 19(1):1-11. PubMed ID: 15629889
    [Abstract] [Full Text] [Related]

  • 9. Abrogation of transforming growth factor-β-induced tissue fibrosis in TBRIcaCol1a2Cre transgenic mice by the second generation tyrosine kinase inhibitor SKI-606 (Bosutinib).
    Wermuth PJ, Jimenez SA.
    PLoS One; 2018 Jan; 13(5):e0196559. PubMed ID: 29718973
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of radiation-induced skin fibrosis with imatinib.
    Horton JA, Chung EJ, Hudak KE, Sowers A, Thetford A, White AO, Mitchell JB, Citrin DE.
    Int J Radiat Biol; 2013 Mar; 89(3):162-70. PubMed ID: 23083077
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis.
    Daniels CE, Wilkes MC, Edens M, Kottom TJ, Murphy SJ, Limper AH, Leof EB.
    J Clin Invest; 2004 Nov; 114(9):1308-16. PubMed ID: 15520863
    [Abstract] [Full Text] [Related]

  • 13. Levels of target activation predict antifibrotic responses to tyrosine kinase inhibitors.
    Maurer B, Distler A, Dees C, Khan K, Denton CP, Abraham D, Gay RE, Michel BA, Gay S, Hw Distler J, Distler O.
    Ann Rheum Dis; 2013 Dec; 72(12):2039-46. PubMed ID: 24013728
    [Abstract] [Full Text] [Related]

  • 14. Intracellular tyrosine kinases as novel targets for anti-fibrotic therapy in systemic sclerosis.
    Distler JH, Distler O.
    Rheumatology (Oxford); 2008 Oct; 47 Suppl 5():v10-1. PubMed ID: 18784126
    [Abstract] [Full Text] [Related]

  • 15. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis.
    Distler JH, Jüngel A, Huber LC, Schulze-Horsel U, Zwerina J, Gay RE, Michel BA, Hauser T, Schett G, Gay S, Distler O.
    Arthritis Rheum; 2007 Jan; 56(1):311-22. PubMed ID: 17195235
    [Abstract] [Full Text] [Related]

  • 16. Imatinib mesylate attenuates myocardial remodeling through inhibition of platelet-derived growth factor and transforming growth factor activation in a rat model of hypertension.
    Jang SW, Ihm SH, Choo EH, Kim OR, Chang K, Park CS, Kim HY, Seung KB.
    Hypertension; 2014 Jun; 63(6):1228-34. PubMed ID: 24591339
    [Abstract] [Full Text] [Related]

  • 17. Effects of the protein kinase inhibitor, imatinib mesylate, on epithelial/mesenchymal phenotypes: implications for treatment of fibrotic diseases.
    Vittal R, Zhang H, Han MK, Moore BB, Horowitz JC, Thannickal VJ.
    J Pharmacol Exp Ther; 2007 Apr; 321(1):35-44. PubMed ID: 17218487
    [Abstract] [Full Text] [Related]

  • 18. Are tyrosine kinase inhibitors promising for the treatment of systemic sclerosis and other fibrotic diseases?
    Beyer C, Distler JH, Distler O.
    Swiss Med Wkly; 2010 Apr; 140():w13050. PubMed ID: 20419513
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.